NO944700L - Nye tienotiazinderivater, fremgangsmåte for fremstilling derav samt farmasöytiske preparater inneholdende forbindelsene - Google Patents

Nye tienotiazinderivater, fremgangsmåte for fremstilling derav samt farmasöytiske preparater inneholdende forbindelsene

Info

Publication number
NO944700L
NO944700L NO944700A NO944700A NO944700L NO 944700 L NO944700 L NO 944700L NO 944700 A NO944700 A NO 944700A NO 944700 A NO944700 A NO 944700A NO 944700 L NO944700 L NO 944700L
Authority
NO
Norway
Prior art keywords
substituted
aryl
lower alkyl
heteroaryl
heteroatoms
Prior art date
Application number
NO944700A
Other languages
English (en)
Other versions
NO944700D0 (no
Inventor
Dieter Binder
Josef Weinberger
Original Assignee
Chem Pharm Forsch Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AT253093A external-priority patent/AT400437B/de
Priority claimed from AT253193A external-priority patent/AT400567B/de
Priority claimed from AT102694A external-priority patent/AT400568B/de
Application filed by Chem Pharm Forsch Gmbh filed Critical Chem Pharm Forsch Gmbh
Publication of NO944700D0 publication Critical patent/NO944700D0/no
Publication of NO944700L publication Critical patent/NO944700L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

Det er beskrevet nye tlenotlazln-derlvater med generell formel: hvori: o o," s- N M-Q-R \\ f OR, (D A betyr laverealkyl, perfluorert laverealkyl, laverealkyl - oksy, halogen, nltro, cyano eller en mono- eller polycykllsk 5-12-leddet, eventuelt delvis hydrert aryl- eller heteroaryl- rest med 1-4 heteroatomer som O, S og N, som eventuelt kan være substituert med laverealkyl, per fluor laverealkyl , aryl, heteroaryl, substituert aryl, substituert hetero- aryl, halogen, laverealkoksy, aryloksy, substituert aryloksy, heteroaryloksy , substituert heteroaryloksy og nltro, hvori de aktuelle substltuentene l substituert aryl, substituert heteroaryl, substituert aryloksy og substituert heteroaryloksy betyr halogen, laverealkyl, perfluorlaverealkyl , laverealkoksy og lignende; w D betyr en 2-pyridylrest eller en rest X^TY , hvorved X og Y uavhengig av hverandre betyr CH, NR6, O eller S, hvor R6 betyr hydrogen eller laverealkyl, M betyr en enkeltbinding, en rettkjedet eller forgrenet hydrokarbonkjede med 1-12 karbonatomer i kjeden, hvorved denne kjeden kan inneholde en eller flere dobbelt- og/eller trippelbindinger og/eller et eller flere hetero- atomer som O, S og N, en 5-12-leddet mono- eller polycykllsk, eventuelt delvis hydrert aryl- eller heteroaryl- rest med 1-4 heteroatomer som O, S og N, som kan være substituert med halogen, laverealkyl eller laverealkoksy; O betyr en enkeltbinding eller et heteroatom som O, S og N; R betyr hydrogen, en 5-12-leddet mono- eller polycykllsk aryl- eller heteroaryl rest med 1-4 heteroatomer sera O, S og N, som eventuelt kan være delvis hydrert, eller også kan være substituert en eller flere ganger med halogen, laverealkyl eller laverealkoksy; R, O l ^^ og R! betyr hydrogen eller ¿ nvorl R2 betyr laverealkyl og #3 betyr laverealkyl, aryl eller -OR4, hvor R4 betyr laverealkyl, cykloalkyl med 4-8 karbonatomer eller aryl; samt deres farmasøytisk anvendbare salter. Det er videre beskrevet fremgangsmåter for fremstilling av forbin- delsene samt deres anvendelse ved fremstilling av legemidler.
NO944700A 1993-12-14 1994-12-06 Nye tienotiazinderivater, fremgangsmåte for fremstilling derav samt farmasöytiske preparater inneholdende forbindelsene NO944700L (no)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AT253093A AT400437B (de) 1993-12-14 1993-12-14 Neue n-heterocyclische thienothiazincarboxamide, verfahren zu ihrer herstellung und ihre verwendung
AT253193A AT400567B (de) 1993-12-14 1993-12-14 Neue arylsubstituierte thienothiazinderivate, verfahren zu ihrer herstellung und ihre verwendung
AT102694A AT400568B (de) 1994-05-18 1994-05-18 Neue n-heterocyclische thienothiazincarboxamide, verfahren zu ihrer herstellung und ihre verwendung

Publications (2)

Publication Number Publication Date
NO944700D0 NO944700D0 (no) 1994-12-06
NO944700L true NO944700L (no) 1995-06-15

Family

ID=27146994

Family Applications (1)

Application Number Title Priority Date Filing Date
NO944700A NO944700L (no) 1993-12-14 1994-12-06 Nye tienotiazinderivater, fremgangsmåte for fremstilling derav samt farmasöytiske preparater inneholdende forbindelsene

Country Status (6)

Country Link
US (1) US5679678A (no)
EP (1) EP0658559A1 (no)
JP (1) JPH07267964A (no)
CN (1) CN1109059A (no)
CA (1) CA2137976A1 (no)
NO (1) NO944700L (no)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6043232A (en) * 1997-07-23 2000-03-28 Nitromed, Inc. Nitroso esters of beta-oxo-amides and aryl propionic acid derivatives of non-steroidal antiinflammatory drugs
US5703073A (en) * 1995-04-19 1997-12-30 Nitromed, Inc. Compositions and methods to prevent toxicity induced by nonsteroidal antiinflammatory drugs
EP1126838A4 (en) 1998-10-30 2005-02-16 Nitromed Inc NITROSIS AND NITROSYAL NON-STEROID ANTI-INFLAMMATORY COMPOUNDS, COMPOSITIONS AND METHODS OF USE
CA2353961A1 (en) * 1998-12-25 2000-07-06 Shionogi & Co., Ltd. Heteroaromatic derivatives having an inhibitory activity against hiv integrase
AU6016200A (en) * 1999-07-16 2001-02-05 Sankyo Company Limited Coumarone analogues
EP1288199A4 (en) * 2000-04-28 2005-10-12 Shionogi & Co INHIBITORS OF MMP-12
EP2363396A1 (en) 2001-06-11 2011-09-07 Virochem Pharma Inc. Thiophene derivatives as antiviral agents for flavivirus infection
US8329924B2 (en) * 2001-06-11 2012-12-11 Vertex Pharmaceuticals (Canada) Incorporated Compounds and methods for the treatment or prevention of Flavivirus infections
CN1171892C (zh) 2001-06-25 2004-10-20 李晶 具有抗炎镇痛活性的噻吩并噻嗪化合物及其制备方法和用途
GB0203412D0 (en) * 2002-02-13 2002-04-03 Pharmagene Lab Ltd 5-HT 2B receptor antagonists
US20050176791A1 (en) * 2002-02-13 2005-08-11 Oxford Alexander W. 5-HT2B receptor antagonists
AU2003207299A1 (en) * 2002-02-13 2003-09-04 Pharmagene Laboratories Limited 5-ht2b receptor antagonists
PT1569929E (pt) 2002-12-10 2010-06-18 Virochem Pharma Inc Compostos e métodos para o tratamento ou prevenção de infecções por flavivírus
EP1648876A1 (en) * 2003-07-24 2006-04-26 Pharmagene Laboratories Ltd 5-ht sb 2b /sb receptor antagonists
SI2104674T1 (sl) 2006-11-15 2013-09-30 Vertex Pharmaceuticals (Canada) Incorporated Tiofenski analogi za zdravljenje ali preprečevanje flavivirusnih infekcij
LT3141542T (lt) 2011-12-28 2020-09-25 Global Blood Therapeutics, Inc. Pakeistieji benzaldehido junginiai ir jų panaudojimas didinant audinių aprūpinimą deguonimi
EP2797597B1 (en) 2011-12-28 2020-02-26 Global Blood Therapeutics, Inc. Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation
EP2832731A4 (en) * 2012-03-27 2015-08-19 Shionogi & Co AROMATIC HETEROCYCLIC CHAIN 5-CORE DERIVED DERIVATIVE HAVING TRPV4 INHIBITORY ACTIVITY
US10266551B2 (en) 2013-03-15 2019-04-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
SG11201507349TA (en) 2013-03-15 2015-10-29 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US9802900B2 (en) 2013-03-15 2017-10-31 Global Blood Therapeutics, Inc. Bicyclic heteroaryl compounds and uses thereof for the modulation of hemoglobin
WO2014145040A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation
US9458139B2 (en) 2013-03-15 2016-10-04 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US9422279B2 (en) 2013-03-15 2016-08-23 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
PE20160078A1 (es) 2013-03-15 2016-03-02 Global Blood Therapeutics Inc Compuestos y sus usos para modular la hemoglobina
SG10201802911RA (en) 2013-03-15 2018-05-30 Global Blood Therapeutics Inc Compounds and uses thereof for the modulation of hemoglobin
US8952171B2 (en) 2013-03-15 2015-02-10 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
US20140274961A1 (en) 2013-03-15 2014-09-18 Global Blood Therapeutics, Inc. Compounds and uses thereof for the modulation of hemoglobin
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
SG10201804139VA (en) 2014-02-07 2018-06-28 Global Blood Therapeutics Inc Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde
MA41841A (fr) 2015-03-30 2018-02-06 Global Blood Therapeutics Inc Composés aldéhyde pour le traitement de la fibrose pulmonaire, de l'hypoxie, et de maladies auto-immunes et des tissus conjonctifs
MX2018006832A (es) 2015-12-04 2018-11-09 Global Blood Therapeutics Inc Regimenes de dosificacion de 2-hidroxi-6-((2-(1-isopropil-1h-piraz ol-5-il)-piridin-3-il)-metoxi)-benzaldehido.
TWI825524B (zh) 2016-05-12 2023-12-11 美商全球血液治療公司 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法
TWI778983B (zh) 2016-10-12 2022-10-01 美商全球血液治療公司 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑
CN106632403B (zh) * 2017-01-23 2018-09-11 牡丹江医学院 一种手术用止痛消炎药及其制备方法
ES2966707T3 (es) 2018-10-01 2024-04-23 Global Blood Therapeutics Inc Moduladores de la hemoglobina para el tratamiento de la drepanocitosis
RS62970B1 (sr) 2018-11-19 2022-03-31 Global Blood Therapeutics Inc 2-formil-3-hidroksifeniloksimetil jedinjenja sposobna da moduliraju hemoglobin
CN111646987B (zh) * 2020-06-05 2022-06-24 湖南师范大学 一种5-氨基噻唑类非甾体抗炎化合物及其制备方法和用途

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL47877A (en) * 1974-08-26 1978-10-31 Sparamedica Ag Thienothiazine carboxamide derivatives,their manufacture and pharmaceutical compositions containing them
CH619236A5 (en) * 1975-08-14 1980-09-15 Hoffmann La Roche Process for the preparation of thienothiazine derivatives
AU518216B2 (en) * 1977-09-06 1981-09-17 Hafslund Nycomed Pharma Aktiengesellschaft Thienothiazine derivatives
DE3371082D1 (de) * 1982-09-09 1987-05-27 Hoffmann La Roche Thieno(2,3-e)-1,2-thiazine derivatives
NZ226477A (en) * 1987-10-29 1990-07-26 Cl Pharma Substituted thieno (2,3-e)-1,2 thiazine derivatives and pharmaceutical compositions
AT399880B (de) * 1992-07-03 1995-08-25 Chem Pharm Forsch Gmbh Neue thienothiazinderivate, verfahren zu ihrer herstellung und ihre verwendung

Also Published As

Publication number Publication date
CN1109059A (zh) 1995-09-27
EP0658559A1 (de) 1995-06-21
JPH07267964A (ja) 1995-10-17
US5679678A (en) 1997-10-21
CA2137976A1 (en) 1995-06-15
NO944700D0 (no) 1994-12-06

Similar Documents

Publication Publication Date Title
NO944700L (no) Nye tienotiazinderivater, fremgangsmåte for fremstilling derav samt farmasöytiske preparater inneholdende forbindelsene
DK0687253T3 (da) Hidtil ukendte 4-aminopyridiner, fremgangsmåde til deres fremstilling samt lægemidler indeholdende disse forbindelser
US3488423A (en) Process for producing anti-inflammatory effects and compositions
DE68906552D1 (de) Camptothecin-derivate und verfahren zu ihrer herstellung.
IL129724A0 (en) Crystals of benzimidazole derivatives and their production
AP9701039A0 (en) Derivatives of 2- (2-oxo-ethlidene)-imidazolidin-4-one.
UA8022A1 (uk) Спосіб одержання похідних бензімідазолу у вигляді суміші ізомерів або індивідуальних ізомерів у вільному вигляді або у вигляді їх фізіологічно прийнятих солей
CA2161542A1 (en) Novel 5-Pyrrolyl-2-Pyridylmethylsulfinyl Benzimidazole Derivatives
NO970293L (no) Substituerte camptothecinderivater og fremgangsmåte for deres fremstilling
TW368501B (en) 7-(2-aminoethyl)-benzothiazolones
SE7501365L (no)
UA8017A1 (uk) Спосіб отримання похідних хінолінкарбонової кислоти
AU2186288A (en) Novel amide compounds, process for preparing the same, and composition for activating gastric motor function containing the same
NO944680L (no) Nye tienotiazinerivater, en fremgangsmåte til fremstilling derav samt deres anvendelse
ES2016017A6 (es) Procedimiento para preparar derivados de acido 1,1-dioxocefem-4-carbotiolico.
NO932129L (no) Fremgangsmaate for fremstilling og anvendelse av nye tienotiazinderivater
ATE168371T1 (de) 5-amino-5,6,7,8-tetrahydrochinoline und verwandte verbindungen, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel
DK0432841T3 (da) Spiro-indolin-oxazin-forbindelser med fotokromatiske og fotosensibiliserende egenskaber samt fremgangsmåde til deres fremstilling
NO920619L (no) Oxazinobenzazolforbindelser
EP0621268A4 (en) NEW AZOLE DERIVATIVE, ITS PRODUCTION AND PHARMACEUTICAL COMPOSITION.
HU903511D0 (en) Process for producing aminoketone derivatives and pharmaceutical preparatives containing these compounds
GB898409A (en) Process for the manufacture of 2-amino-ú=-triazolo[2,3-c]pyrimidines
DE3679257D1 (de) 4-cyanopiperidine-derivate, herstellung und anwendung.
NO934881L (no) Benzotiazolderivater, fremgangsmåte for deres fremstilling og farmasöytisk preparat derav
ES8106000A1 (es) Un procedimiento para la preparacion de pirimido-2-benzace- pinas